DMTRF.US 3-D Matrix Ltd
- Market cap
- USD 310M
- P/E
- 14.3x
- P/B
- 6.83x
- ROE
- 17.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is DMTRF.US undervalued?
Graham numberDMTRF.US trades 108.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
3-D Matrix Ltd fundamental analysis
No fundamental analysis for 3-D Matrix Ltd yet.
3-D Matrix Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 3-D Matrix Ltd
3-D Matrix, Ltd. developing, manufacturing, and selling self-assembling peptide technology in Japan and internationally. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the regenerative medicine, cell therapy, drug delivery systems, and other uses in various fields; and surfactant-like peptide, as well as High Concentration PuraMatrix, a high concentration hydrogel; and GMP Grade PuraMatrix. The company was incorporated in 2004 and is based in Tokyo, Japa…
Full company profile3-D Matrix Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
3-D Matrix Ltd annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 616M | 229M | 329M | 672M | 1.02B | 1.51B | 2.31B | 4.59B | 6.93B | 10.9B | 13.2B |
| Gross Profit | 514M | 51.4M | 16.7M | 112M | 305M | 661M | 1.29B | 3.09B | 4.42B | 8.56B | 10.6B |
| Operating Income | -1.24B | -1.87B | -2.27B | -2.54B | -2.65B | -2.74B | -3.16B | -2.12B | -1.16B | 1.33B | 2.03B |
| EBITDA | -1.16B | 18.7M | -277M | -552M | 642M | 847M | 775M | 2.18B | -1.25B | 1.33B | 2.03B |
| Net Income | -1.39B | -1.87B | -2.55B | -3.10B | -2.01B | -1.89B | -2.45B | -256M | -2.50B | 4.15B | 1.24B |
| EPS | -65 | -81 | -97 | -103 | -50 | -37 | -41 | -3.49 | -25 | 31 | 9.28 |
| Balance Sheet | |||||||||||
| Total Assets | 3.42B | 3.14B | 4.09B | 3.12B | 3.51B | 5.61B | 5.83B | 5.89B | 6.51B | 9.78B | 9.35B |
| Total Liabilities | 816M | 934M | 2.58B | 2.64B | 1.85B | 4.15B | 5.30B | 5.53B | 4.30B | 2.99B | 2.17B |
| Shareholders' Equity | 2.61B | 2.20B | 1.51B | 473M | 1.66B | 1.46B | 525M | 353M | 2.22B | 6.79B | 7.18B |
| Cash & Short-term Investments | 1.75B | 1.16B | 1.80B | 1.06B | 1.14B | 2.85B | 1.17B | 1.36B | 1.58B | 2.83B | 1.68B |
| Total Debt | 450M | 450M | 1.85B | 1.80B | 1.46B | 3.67B | 4.37B | 4.17B | 2.94B | 599M | 597M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.89B | -2.02B | -2.30B | -2.19B | -3.25B | -2.90B | -4.59B | -1.90B | -1.71B | 396M | - |
| Capital Expenditure | 138M | 92.1M | 136M | 111M | 156M | 80.8M | 68.0M | 4.33M | 12.3M | 27.9M | 0.00 |
| Free Cash Flow | -2.03B | -2.11B | -2.44B | -2.30B | -3.41B | -2.98B | -4.65B | -1.90B | -1.73B | 368M | - |
| Ratios | |||||||||||
| ROE | -53.4% | -84.8% | -168.8% | -654.6% | -121.3% | -130.0% | -466.1% | -72.3% | -112.9% | 61.1% | 17.3% |
| ROA | -40.7% | -59.5% | -62.4% | -99.4% | -57.4% | -33.8% | -42.0% | -4.3% | -38.4% | 42.4% | 13.3% |
| Net Profit Margin | -226.1% | -816.3% | -776.8% | -460.5% | -196.5% | -125.8% | -105.7% | -5.6% | -36.1% | 38.2% | 9.4% |
| Debt to Equity | 0.17x | 0.20x | 1.22x | 3.81x | 0.88x | 2.51x | 8.33x | 11.81x | 1.33x | 0.09x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
3-D Matrix Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 2.00K | 0.00 | - |
| 2019 | USD 1.00K | 0.00 | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on May 29, 2013.
Who owns 3-D Matrix Ltd
- Insiders 5.86%
- Institutions 7.13%
- Public & others 87.01%
- Shares outstanding 128M
- Free float 120M
3-D Matrix Ltd company profile
- Company name
- 3-D Matrix Ltd
- Ticker
- DMTRF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 129
- Fiscal year end
- April
- Address
- Kojimachi HF Building, Tokyo, Japan, 102-0083
- Phone
- 81 3 3511 3440
- Website
- 3d-matrix.co.jp
About 3-D Matrix Ltd
3-D Matrix, Ltd. developing, manufacturing, and selling self-assembling peptide technology in Japan and internationally. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the regenerative medicine, cell therapy, drug delivery systems, and other uses in various fields; and surfactant-like peptide, as well as High Concentration PuraMatrix, a high concentration hydrogel; and GMP Grade PuraMatrix. The company was incorporated in 2004 and is based in Tokyo, Japan.
3-D Matrix Ltd management
5- Mr. Keiji Nagano MBAExecutive Chairman of the Board · born 1954
- Mr. Toshi AmanumaPresident & Representative Director · born 1975
- Dr. Shuguang Zhang Ph.D.Founder
- Mr. Satoru KobayashiExecutive Officer, Head of Business Development & Director · born 1980
- Mr. Hisato YutoExecutive Officer